Olivier Cussenot
Overview
Explore the profile of Olivier Cussenot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
317
Citations
8328
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matsukawa A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, Fazekas T, Tsuboi I, et al.
Eur Urol Focus
. 2025 Jan;
PMID: 39848859
Background And Objective: There is an established association between secondary bladder cancers (SBCs) and radiotherapy (RT) for prostate cancer (PC), which remains a significant concern. Our aim was to update...
2.
Cussenot O, Poupel L, Mousset C, Lavergne J, Bruyere F, Fontaine A, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796635
Purpose: To identify molecular changes during PCa invasion of adipose space using Spatial Transcriptomic Profiling of PCa cells. Methods: This study was performed on paired intraprostatic and extraprostatic samples obtained...
3.
Erickson A, Figiel S, Rajakumar T, Rao S, Yin W, Doultsinos D, et al.
PLoS One
. 2025 Jan;
20(1):e0316475.
PMID: 39752458
Epithelial cancers are typically heterogeneous with primary prostate cancer being a typical example of histological and genomic variation. Prior studies of primary prostate cancer tumour genetics revealed extensive inter and...
4.
Cussenot O, Roupret M, Shariat S
Eur Urol Oncol
. 2024 Dec;
8(1):7-8.
PMID: 39721830
Current epidemiological indicators reflect the prevalence of prostate-specific antigen (PSA) testing rather than the actual incidence of clinically significant prostate cancer. These indicators are also biased because of the variability...
5.
Srinivasan S, Kryza T, Bock N, Tse B, Sokolowski K, Janaththani P, et al.
Nat Commun
. 2024 Nov;
15(1):9587.
PMID: 39505858
Genetic variation at the 19q13.3 KLK locus is linked with prostate cancer susceptibility in men. The non-synonymous KLK3 single nucleotide polymorphism (SNP), rs17632542 (c.536 T > C; Ile163Thr-substitution in PSA)...
6.
Wasinger G, Cussenot O, Comperat E
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730601
Intraductal carcinoma of the prostate (IDC-P) has emerged as a distinct entity with significant clinical implications in prostate cancer (PCa) management. Despite historically being considered an extension of invasive PCa,...
7.
Cussenot O, Chambaz A, Hamdy F
Eur Urol
. 2024 Mar;
86(2):e48-e49.
PMID: 38492978
No abstract available.
8.
Cussenot O, Taille Y, Portal J, Cancel-Tassin G, Roupret M, De La Taille A, et al.
Eur Urol Oncol
. 2024 Mar;
7(5):978-981.
PMID: 38472031
We report nationwide real-life practice in the management of prostate cancer (PC) in France in a population of 4936750 men. All prostate-specific antigen (PSA) blood tests performed between 2006 and...
9.
Zhang K, Stricker P, Lohr M, Stehling M, Suberville M, Cussenot O, et al.
Prostate Cancer Prostatic Dis
. 2024 Jan;
27(3):525-530.
PMID: 38195916
Background: Irreversible electroporation (IRE) is a novel technique to treat localized prostate cancer with the aim of achieving oncological control while reducing related side effects. We present the outcomes of...
10.
Cussenot O, Timms K, Perrot E, Blanchet P, Brureau L, Solimeno C, et al.
Eur Urol Oncol
. 2024 Jan;
7(3):597-604.
PMID: 38182487
Background: Visceral metastases are known to occur in advanced prostate cancer, usually when the tumour is resistant to androgen deprivation and, have worse outcomes regardless of therapies. Objective: To analyse...